Optimizing Timing of rhPSMA-7.3 (18F) for Assessing Site(s) of Recurrent Disease Following Radical Prostatectomy
Active, not recruiting · Phase 3 · NCT05678322
Conditions: Prostate Cancer
At a glance
- Research payments reported, 2025
- $10,132
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 26
About the trial
- Sponsor
- NYU Langone Health (with Blue Earth Diagnostics)
- Tested
- 18F-Labeled Positron Emission Tomography (PET) Diagnostic Agent (drug), PET MRI Imaging (device)
- Dates
- Started 2023-01-31; completion 2026-11
- Results posted
- Yes
All men following Radical Prostatectomy (RP) at NYU Langone Health undergo routine prostate specific antigen (PSA) testing in order to identify disease recurrence. By consensus, a BCR following RP occurs once the PSA \> 0.2 ng/ml/ Biochemical recurrence often develops years prior to clinical evidence of disease recurrence. Early identification of the site(s) of disease recurrence enables early salvage intervention. Men will be eligible for the study at the point in time their post-prostatectomy PSA level first becomes \>0.2 ng/ml. Only those patients with rhPSMA-7.3 (18F) identifiable disease (local, nodal or systemic) will be offered salvage intervention per standard of care. All patient…
From ClinicalTrials.gov, last updated 2026-03-25. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Blue Earth Diagnostics reported $10,132 in research payments for this study in 2025 (2 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- NYU School of Medicine $10,132
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.